MA45150A - Modulateurs du récepteur adrénergique-bêta-3 utiles pour le traitement et la prevention de troubles associes a ce dernier - Google Patents

Modulateurs du récepteur adrénergique-bêta-3 utiles pour le traitement et la prevention de troubles associes a ce dernier

Info

Publication number: MA45150A
Authority: MA; Morocco
Prior art keywords: adrenergic; beta; prevention; treatment; disorders associated
Prior art date: 2016-06-06

Application number

MA045150A

Other languages

English (en)

Inventor

Anthony C Blackburn

Quyen-Quyen Do

Maiko Nagura

Thuy-Anh Tran

Brett Ullman

Original Assignee

Arena Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-06-06

Filing date

2017-06-05

Publication date

2021-05-05

2017-06-05 Application filed by Arena Pharm Inc filed Critical Arena Pharm Inc

2021-05-05 Publication of MA45150A publication Critical patent/MA45150A/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Hydrogenated Pyridines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

MA045150A 2016-06-06 2017-06-05 Modulateurs du récepteur adrénergique-bêta-3 utiles pour le traitement et la prevention de troubles associes a ce dernier MA45150A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201662346293P	2016-06-06	2016-06-06

Publications (1)

Publication Number	Publication Date
MA45150A true MA45150A (fr)	2021-05-05

Family

ID=59067920

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
MA44037A MA44037B1 (fr)	2016-06-06	2017-06-04	Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
MA045150A MA45150A (fr)	2016-06-06	2017-06-05	Modulateurs du récepteur adrénergique-bêta-3 utiles pour le traitement et la prevention de troubles associes a ce dernier

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
MA44037A MA44037B1 (fr)	2016-06-06	2017-06-04	Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci

Country Status (29)

Country	Link
US (5)	US20190284200A1 (fr)
EP (1)	EP3464292B8 (fr)
JP (3)	JP6771246B2 (fr)
KR (2)	KR20190026731A (fr)
CN (1)	CN109563103B (fr)
AR (1)	AR108772A1 (fr)
AU (2)	AU2017278102B2 (fr)
CA (1)	CA3026024C (fr)
CL (1)	CL2018003451A1 (fr)
CO (1)	CO2019000041A2 (fr)
CR (1)	CR20180595A (fr)
DK (1)	DK3464292T3 (fr)
EA (1)	EA201892817A1 (fr)
EC (1)	ECSP19001018A (fr)
ES (1)	ES2929737T3 (fr)
IL (2)	IL289378B (fr)
MA (2)	MA44037B1 (fr)
MX (2)	MX387995B (fr)
MY (1)	MY195982A (fr)
NI (1)	NI201800130A (fr)
NZ (1)	NZ749202A (fr)
PE (1)	PE20190445A1 (fr)
PH (1)	PH12018502550B1 (fr)
PT (1)	PT3464292T (fr)
SG (1)	SG11201810788QA (fr)
TN (1)	TN2018000391A1 (fr)
TW (2)	TWI752963B (fr)
UA (1)	UA125120C2 (fr)
WO (1)	WO2017214002A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MA44037B1 (fr)	2016-06-06	2020-03-31	Arena Pharm Inc	Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
PT3448859T (pt)	2017-03-20	2019-10-25	Forma Therapeutics Inc	Composições de pirrolopirrole como ativadores de piruvato quinase (pkr).
JP7357617B2 (ja) *	2017-12-06	2023-10-06	アリーナファーマシューティカルズ，インコーポレイテッド	心不全およびそれに関連する障害の治療または予防に有用なβ－３アドレナリン受容体のモジュレーター
ES2989438T3 (es)	2018-09-19	2024-11-26	Novo Nordisk Healthcare Ag	Activación de la piruvato cinasa R
US12053458B2 (en)	2018-09-19	2024-08-06	Novo Nordisk Health Care Ag	Treating sickle cell disease with a pyruvate kinase R activating compound
CN114615977B (zh)	2019-09-19	2025-01-14	诺沃挪第克健康护理股份公司	丙酮酸激酶r(pkr)活化组合物
US12128035B2 (en)	2021-03-19	2024-10-29	Novo Nordisk Health Care Ag	Activating pyruvate kinase R
JP2023024954A (ja) *	2021-08-09	2023-02-21	アリーナファーマシューティカルズ，インコーポレイテッド	ベータ－３アドレナリン作動性受容体に関連する障害の処置または予防に有用なベータ－３アドレナリン作動性受容体のモジュレーター
US20240358689A1 (en) *	2021-08-26	2024-10-31	Arena Pharmaceuticals, Inc.	Modulators Of The Beta-3 Adrenergic Receptor Useful For The Treatment Or Prevention Of Renal Cystic Disease and Cardiorenal Syndrome
JP2024536333A (ja)	2021-10-06	2024-10-04	アリーナファーマシューティカルズ，インコーポレイテッド	それに関連する障害の処置または予防に有用なベータ－３アドレナリン作動性受容体のモジュレーター
US20250152574A1 (en) *	2022-02-14	2025-05-15	Biogen Ma Inc.	Emopamil-binding protein inhibitors and uses thereof
CN114539103B (zh) *	2022-03-21	2023-04-07	佳木斯黑龙农药有限公司	2-二氟乙氧基-6-三氟甲基苯磺酰氯的合成方法
CN116178220A (zh) *	2022-12-13	2023-05-30	爱斯特（成都）生物制药股份有限公司	一种制备(2s)-2-[[3-(甲基磺酰基l)苯氧基]甲基]环氧乙烷的方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3028340C2 (de) *	1980-07-25	1987-02-05	Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe	Amino-desoxy-1.4;3.6-dianhydro-hexit-nitrate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
US5254595A (en)	1988-12-23	1993-10-19	Elf Sanofi	Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them
FR2751646B1 (fr)	1996-07-23	1999-01-22	Sanofi Sa	Phenoxypropanolamine a action antagoniste beta3-adrenergique
WO1998027080A1 (fr)	1996-12-19	1998-06-25	Agrevo Uk Limited	Chromones utiles en tant que fongicides
FR2780057B1 (fr) *	1998-06-18	2002-09-13	Sanofi Sa	Phenoxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant
JP4782342B2 (ja) *	1999-12-17	2011-09-28	サノフィ−アベンティス	フェノキシプロパノールアミン類、それらの製造方法およびそれらを含む医薬組成物
DE20204129U1 (de)	2002-03-15	2002-07-25	Wella Ag, 64295 Darmstadt	Mittel zur Färbung von Keratinfasern mit Chinolinium-Farbstoffen
WO2005092860A1 (fr) *	2004-03-23	2005-10-06	Pfizer Limited	Composes servant au traitement de maladies
EP1833480A2 (fr) *	2004-11-30	2007-09-19	Artesian Therapeutics, Inc.	Composes cardiotoniques dotes d'une activite inhibitrice dirigee contre les recepteurs beta-adrenergiques et la phosphodiesterase
US8697674B2 (en)	2004-12-29	2014-04-15	Naturon, Inc.	Xanthurenic acid derivative pharmaceutical compositions and methods related thereto
WO2008094507A2 (fr)	2007-01-26	2008-08-07	Cellicon Biotechnologies, Inc.	Nouveaux composés de fusion
US8039505B2 (en)	2007-04-11	2011-10-18	University Of Utah Research Foundation	Compounds for modulating T-cells
US8722851B2 (en)	2007-11-02	2014-05-13	Pain Therapeutics, Inc.	Analgesia with minimal tolerance and dependence by a mu opioid receptor agonist that also binds filamin A
US20100279997A1 (en)	2009-05-04	2010-11-04	Lindsay Burns Barbier	Analgesic that binds filamin a
EP2488177B1 (fr)	2008-10-31	2016-10-12	Pain Therapeutics, Inc.	Anti-inflammatoire et analgésique se liant à la filamine a
AU2009308769B2 (en)	2008-10-31	2015-03-12	Pain Therapeutics, Inc.	Filamin A-binding anti-inflammatory analgesic
CA2741839A1 (fr) *	2008-11-21	2010-05-27	Pfizer Inc.	1-oxa-8-azaspiro[4.5]decane-8-carboxamides en tant qu'inhibiteurs de faah
WO2011137024A1 (fr) *	2010-04-26	2011-11-03	Merck Sharp & Dohme Corp.	Nouveaux inhibiteurs de spiropipéridine prolylcarboxypeptidase
EP2595483B1 (fr) *	2010-07-23	2017-03-22	Merck Sharp & Dohme Corp.	Nouveaux agonistes du récepteur 3-adrénergique dérivés de la pyrrolidine
JP2012092038A (ja)	2010-10-26	2012-05-17	F Hoffmann La Roche Ag	糖尿病、糖尿病関連疾患又は糖尿病性合併症の予防又は治療剤
DK2882428T3 (en)	2012-07-13	2019-04-15	Pain Therapeutics Inc	PROCEDURE TO INHIBIT TAU PHOSPHORIZATION
WO2014012054A1 (fr)	2012-07-13	2014-01-16	Pain Therapeutics, Inc.	Analyse de la maladie d'alzheimer chez un patient vivant
GB201405359D0 (en)	2014-03-25	2014-05-07	Univ Liverpool	Synthetic process
MA44037B1 (fr)	2016-06-06	2020-03-31	Arena Pharm Inc	Modulateurs du récepteur adrénergique bêta 3 utile dans le traitement ou la prévention de troubles associés à ceux-ci
JP7357617B2 (ja) *	2017-12-06	2023-10-06	アリーナファーマシューティカルズ，インコーポレイテッド	心不全およびそれに関連する障害の治療または予防に有用なβ－３アドレナリン受容体のモジュレーター

2017
- 2017-06-04 MA MA44037A patent/MA44037B1/fr unknown
- 2017-06-05 CR CR20180595A patent/CR20180595A/es unknown
- 2017-06-05 TN TNP/2018/000391A patent/TN2018000391A1/en unknown
- 2017-06-05 NZ NZ749202A patent/NZ749202A/en not_active IP Right Cessation
- 2017-06-05 ES ES17730638T patent/ES2929737T3/es active Active
- 2017-06-05 US US16/307,830 patent/US20190284200A1/en not_active Abandoned
- 2017-06-05 KR KR1020197000005A patent/KR20190026731A/ko not_active Withdrawn
- 2017-06-05 EA EA201892817A patent/EA201892817A1/ru unknown
- 2017-06-05 PT PT177306388T patent/PT3464292T/pt unknown
- 2017-06-05 JP JP2019516084A patent/JP6771246B2/ja active Active
- 2017-06-05 CN CN201780047870.6A patent/CN109563103B/zh active Active
- 2017-06-05 CA CA3026024A patent/CA3026024C/fr active Active
- 2017-06-05 SG SG11201810788QA patent/SG11201810788QA/en unknown
- 2017-06-05 DK DK17730638.8T patent/DK3464292T3/da active
- 2017-06-05 EP EP17730638.8A patent/EP3464292B8/fr active Active
- 2017-06-05 UA UAA201900139A patent/UA125120C2/uk unknown
- 2017-06-05 PE PE2018003180A patent/PE20190445A1/es unknown
- 2017-06-05 MA MA045150A patent/MA45150A/fr unknown
- 2017-06-05 AU AU2017278102A patent/AU2017278102B2/en active Active
- 2017-06-05 MX MX2018015124A patent/MX387995B/es unknown
- 2017-06-05 MY MYPI2018002257A patent/MY195982A/en unknown
- 2017-06-05 KR KR1020227004041A patent/KR102408272B1/ko active Active
- 2017-06-05 IL IL289378A patent/IL289378B/en unknown
- 2017-06-05 PH PH1/2018/502550A patent/PH12018502550B1/en unknown
- 2017-06-05 WO PCT/US2017/035867 patent/WO2017214002A1/fr not_active Ceased
- 2017-06-06 TW TW106118610A patent/TWI752963B/zh active
- 2017-06-06 AR ARP170101546A patent/AR108772A1/es active IP Right Grant
- 2017-06-06 TW TW110147004A patent/TWI784840B/zh active
2018
- 2018-11-20 IL IL263148A patent/IL263148B/en unknown
- 2018-12-03 CL CL2018003451A patent/CL2018003451A1/es unknown
- 2018-12-05 MX MX2021014043A patent/MX2021014043A/es unknown
- 2018-12-05 NI NI201800130A patent/NI201800130A/es unknown
2019
- 2019-01-04 CO CONC2019/0000041A patent/CO2019000041A2/es unknown
- 2019-01-07 EC ECSENADI20191018A patent/ECSP19001018A/es unknown
- 2019-06-04 US US16/431,209 patent/US10479797B2/en active Active
- 2019-09-06 US US16/563,353 patent/US10662200B2/en active Active
2020
- 2020-05-12 US US16/872,812 patent/US10927123B2/en active Active
- 2020-09-18 JP JP2020157196A patent/JP7083087B2/ja active Active
- 2020-12-14 US US17/120,759 patent/US11560386B2/en active Active
2021
- 2021-07-20 AU AU2021206809A patent/AU2021206809B2/en active Active
2022
- 2022-04-21 JP JP2022069821A patent/JP7449329B2/ja active Active

Also Published As

Publication number	Publication date
SG11201810788QA (en)	2018-12-28
MA44037B1 (fr)	2020-03-31
BR112018075201A2 (pt)	2019-03-19
CN109563103B (zh)	2022-05-27
PE20190445A1 (es)	2019-03-29
EP3464292B1 (fr)	2022-09-21
PT3464292T (pt)	2022-11-15
IL263148A (en)	2018-12-31
US20190389875A1 (en)	2019-12-26
PH12018502550A1 (en)	2019-11-04
ES2929737T3 (es)	2022-12-01
CO2019000041A2 (es)	2019-04-30
US20210340154A1 (en)	2021-11-04
AU2021206809A1 (en)	2021-08-12
AU2017278102A1 (en)	2019-01-17
US10927123B2 (en)	2021-02-23
UA125120C2 (uk)	2022-01-12
MY195982A (en)	2023-02-27
EP3464292A1 (fr)	2019-04-10
CN109563103A (zh)	2019-04-02
CR20180595A (es)	2019-04-09
DK3464292T3 (da)	2022-10-31
IL289378B (en)	2022-09-01
NI201800130A (es)	2019-06-13
KR102408272B1 (ko)	2022-06-10
US11560386B2 (en)	2023-01-24
NZ749202A (en)	2022-07-01
ECSP19001018A (es)	2019-02-28
US20190284200A1 (en)	2019-09-19
MX387995B (es)	2025-03-19
US20190292196A1 (en)	2019-09-26
IL263148B (en)	2022-02-01
PH12018502550B1 (en)	2023-01-27
CA3026024A1 (fr)	2017-12-14
AR108772A1 (es)	2018-09-26
JP7083087B2 (ja)	2022-06-10
JP2020203945A (ja)	2020-12-24
MX2021014043A (es)	2022-02-21
IL289378A (en)	2022-02-01
JP6771246B2 (ja)	2020-10-21
EP3464292B8 (fr)	2022-10-26
JP2019518079A (ja)	2019-06-27
TWI784840B (zh)	2022-11-21
AU2017278102B2 (en)	2021-04-29
WO2017214002A1 (fr)	2017-12-14
JP2022089984A (ja)	2022-06-16
KR20190026731A (ko)	2019-03-13
EA201892817A1 (ru)	2019-06-28
TW201803877A (zh)	2018-02-01
JP7449329B2 (ja)	2024-03-13
KR20220025128A (ko)	2022-03-03
AU2021206809B2 (en)	2023-01-05
CA3026024C (fr)	2024-07-02
MA44037A1 (fr)	2019-05-31
TWI752963B (zh)	2022-01-21
US10479797B2 (en)	2019-11-19
US20200270264A1 (en)	2020-08-27
US10662200B2 (en)	2020-05-26
CL2018003451A1 (es)	2019-02-22
TN2018000391A1 (en)	2020-06-15
TW202237619A (zh)	2022-10-01
MX2018015124A (es)	2019-09-09

Publication	Publication Date	Title
MA45150A (fr)	2021-05-05	Modulateurs du récepteur adrénergique-bêta-3 utiles pour le traitement et la prevention de troubles associes a ce dernier
MA46052A (fr)	2021-03-17	Modulateurs du récepteur hormonal pour le traitement d'états et de troubles métaboliques
EP3525735A4 (fr)	2020-03-11	Ultrasons thérapeutiques pour troubles oculaires
EP3692158A4 (fr)	2021-08-04	Thérapies géniques pour troubles lysosomiaux
EP3340982A4 (fr)	2019-03-27	Composés pour le traitement de troubles immunitaires et inflammatoires
EP3481387A4 (fr)	2020-04-08	Methodes et compositions pour le traitement de troubles épileptiques
EP3465212A4 (fr)	2020-01-08	Régulation du microbiote intestinal pour le traitement de troubles neurodégénératifs
EP3410934A4 (fr)	2019-09-11	Procédé et appareil pour le traitement de troubles respiratoires
EP3324965A4 (fr)	2019-07-03	Modulateurs de la gamma-sécrétase pour le traitement de dysfonctionnement du système immunitaire
EP3448398A4 (fr)	2019-12-18	Compositions et méthodes pour le traitement de troubles cutanés
EP3139914C0 (fr)	2023-07-26	Composés pour traiter des maladies et des troubles ophtalmiques
EP3180022A4 (fr)	2019-02-20	Cassette d'expression améliorée pour le conditionnement et l'expression de variantes du facteur viii pour le traitement des troubles de l'hémostase
EP2807412A4 (fr)	2016-01-13	Procédés et systèmes de surveillance nerveuse pour le traitement de troubles pharyngés
MA51075A (fr)	2020-10-14	Procédés et compositions pour traiter des troubles à l'aide de polypeptides de follistatine
EP3331527A4 (fr)	2019-04-10	Procédés de traitement de troubles du développement à l'aide de pipradrol
MA39753A (fr)	2017-01-25	Inhibiteurs de diacylglycérol acyltransférase pour le traitement de troubles métaboliques ou analogues
EP3500267A4 (fr)	2020-03-18	Compositions de nicotinamide riboside et de ptérostilbène et méthodes pour le traitement de troubles neurodégénératifs
EP3432843A4 (fr)	2019-12-11	Vêtement de compression pour troubles neurologiques et circulatoires
MA54925A (fr)	2021-12-22	Compositions pour le traitement de troubles acido-basiques
MA42953A (fr)	2018-08-01	Composés et compositions pour le traitement de troubles oculaires
EP3393496A4 (fr)	2019-07-31	Agoniste de glp-1r à action prolongée pour la thérapie de troubles neurologiques et neurodégénératifs
MA52778A (fr)	2021-04-21	Méthodes de traitement de troubles associés au récepteur s1p1
EP3442547A4 (fr)	2019-11-27	Thérapies à base de probiotiques pour troubles du développement et autres troubles neurologiques
EP3638316A4 (fr)	2021-03-24	Thérapie génique pour troubles oculaires
MA39927A (fr)	2017-03-08	Inhibiteurs de glyt1 pour le traitement de troubles hématologiques